Avantor CEO Emmanuel Ligner to Present at J.P. Morgan Healthcare Conference on January 14
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2026
0mins
Source: Newsfilter
- Conference Appearance: Avantor CEO Emmanuel Ligner is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at approximately 8:15 a.m. Pacific Standard Time, showcasing the company's leadership in the life sciences sector.
- Investor Engagement: The session will be live-streamed via Avantor's investor section on its website, facilitating real-time updates for global investors and enhancing interaction and transparency with stakeholders.
- Replay Availability: A replay of the webcast will be accessible for 30 days post-event, ensuring that investors who cannot attend live can still access critical information, thereby broadening and deepening the company's information dissemination.
- Industry Impact: As a key provider of mission-critical products and services in the life sciences and advanced technology sectors, Avantor's participation will further solidify its influence in the industry and potentially attract more investor interest in its future growth prospects.
Analyst Views on AVTR
Wall Street analysts forecast AVTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVTR is 12.30 USD with a low forecast of 8.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
2 Buy
9 Hold
2 Sell
Hold
Current: 11.650
Low
8.00
Averages
12.30
High
17.00
Current: 11.650
Low
8.00
Averages
12.30
High
17.00
About AVTR
Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
